AP
ALXN

Alydar Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Alydar Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-100,000
Closed -$9.22M – 140
2013
Q2 		$9.22M Buy
+100,000
New +$9.64M 0.5% 49

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Alydar Partners's ALXN Position: Q1 2015 in Review

Alydar Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2015, closing a stake of 100,000 shares — an estimated $18.5M sold.

Alydar Partners first reported a position in ALXN in Q2 2014 and held it in 3 quarters. The position peaked at $24M in Q3 2014. 565 funds tracked by Wall St. Rank hold ALXN as of Q1 2015.

  • Alydar Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Alydar Partners sold 100,000 Alexion Pharmaceuticals shares in Q1 2015, an estimated $18.5M.
  • Alydar Partners first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 3 quarters.
  • Alydar Partners's Alexion Pharmaceuticals position peaked at $24M in Q3 2014.
  • 565 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2015.

Based on Alydar Partners's 13F filing for Q1 2015, filed 15 May 2015.